# Breast Cancer ### Overview The breast cancer evidence focuses on its capacity for apoptosis, PI3K/Akt and MAPK inhibition, angiogenesis suppression, and SOC-treatment-synergy logic. Subtype matters here more than in almost any other cancer area — the ER+, TNBC, and HER2+ pictures are meaningfully different, and the resveratrol overlap adds an extra interpretive layer across all three. ### Key findings * Downregulates CREB phosphorylation and induces apoptosis in MDA-MB-231 and MCF-7 cells * Inhibits PI3K/Akt and MAPK pathways in breast cancer models * Suppresses VEGF and broader angiogenic signalling * Shows synergy with sorafenib and with glucose-metabolism-targeting strategies in preclinical work ### TNBC Triple-negative breast cancer is the subtype where polydatin's direct preclinical signal is strongest and most mechanistically specific. In MDA-MB-231 and SUM159 TNBC cell lines, polydatin combined with the **Nrf2 inhibitor brusatol** significantly inhibited cell proliferation by downregulating the Nrf2/HO-1/NQO1 pathway and driving ROS accumulation — and crucially, the combination achieved this at one-third the dose of either agent alone, reducing toxicity concerns while preserving efficacy in animal models. Separately, polydatin alone induced G2/M cell cycle arrest, apoptosis, and autophagy via ROS/JNK signalling in MDA-MB-231 and MDA-MB-468 TNBC cells. Because polydatin is metabolised toward resveratrol, the broader resveratrol–TNBC literature is directly relevant context. Resveratrol promotes apoptosis in MDA-MB-231 cells through a POLD1-dependent pathway — suppressing POLD1 expression activates caspase-3 cleavage and reduces tumour growth in nude mouse models — and this effect was concentration- and time-dependent, with 50 µM at 36 hours identified as an optimal treatment window. Resveratrol also shows synergy with FL118, leading to G1-phase accumulation and suppression of survival gene expression in TNBC cells. The TNBC landscape is one where the polydatin-to-resveratrol metabolic arc appears to work with, rather than against, the desired anticancer direction. ### ER+ breast cancer The ER+ picture requires greater nuance because resveratrol's behaviour in oestrogen receptor-positive cells is demonstrably biphasic. At low concentrations (around 5 µM), resveratrol stimulated MCF-7 cell proliferation by approximately 21%, while higher concentrations (above 10 µM) shifted to inhibition — a pattern not observed in ER-negative MDA-MB-231 cells. The proposed mechanism involves resveratrol inhibiting the sulphation of estrogen metabolites in MCF-7 cells, thereby paradoxically elevating free estradiol (E2) levels and driving receptor-mediated proliferation at lower doses. This dose-dependency matters when interpreting polydatin studies in MCF-7 cells, since the reported apoptosis-inducing effects occur at concentrations well above the proliferation-stimulating threshold. At higher concentrations, the picture improves: resveratrol activates p53 in MCF-7 and T-47D ER+ cells, contributing to anti-proliferative effects, and modulates NF-Y/p53/Sin3/HDAC1 complexes relevant to tamoxifen-resistant ER+ disease. Polydatin's specific research in MCF-7 involves CREB pathway suppression and induction of apoptosis, which are mechanistically distinct from the resveratrol estrogen-metabolism concern — but the metabolic conversion link means that, in ER+ contexts, dose level and clinical setting warrant careful consideration. This is a "watch this space" area rather than a blanket contraindication, but it warrants explicit acknowledgement in any discussion of ER+ subtypes. ### HER2-specific caution Because polydatin is metabolised toward resveratrol, HER2-positive breast cancer deserves extra caution and clinician review. The most important concern here is not HER2 positivity per se. It is the unresolved Δ16HER2-related resveratrol signal reported in a HER2-positive / ER-positive breast cancer model. That means this is best framed as a HER2-positive/ER-positive *breast-*cancer caution, not a blanket statement about every HER2-positive cancer. For a fuller explanation, see the Polydatin-specific page on [HER2+ Cancers](/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/her2+-cancers.md). ### Practical interpretation Breast cancer is one of the richest mechanistic areas for polydatin, but also one where subtype-specific interpretation matters most. **The TNBC signal — particularly via Nrf2/ROS pathways and the brusatol combination — is the most directly supported by polydatin-specific data.** The ER+ picture carries a resveratrol-related nuance around dose and oestrogen metabolism that warrants caution with ER+ group members. {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} ### References Polydatin down-regulates the phosphorylation level of CREB and induces apoptosis in human breast cancer cells\ Polydatin synergises with 2-deoxyglucose to inhibit PI3K/AKT/HIF-1α/HK2 signalling axis in breast cancer\ Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumour Effect in Breast Cancer by Targeting Nrf2 Signalling Pathway\ Anti-proliferation of triple-negative breast cancer cells with polydatin via ROS/JNK signalling\ Resveratrol mediates the apoptosis of triple-negative breast cancer cells by reducing POLD1 expression\ Resveratrol inhibits key steps of steroid metabolism in ERα+ MCF-7 breast cancer cells\ Resveratrol fuels HER2-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice\ --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/breast-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.